Der REAplan® 3.4 – Ein neues Design mit verbesserter Zugänglichkeit

Anfang 2023 bringt Axinesis die neue Version des Endeffektor-Roboters auf den Markt. Den REAplan® 3.4 Eine verbesserte Benutzerfreundlichkeit und einfachere Anpassungsfähigkeit zeichnen die neue Version 3.4 aus.

Dank des Feedbacks der Therapeuten:innen, die den REAplan® im Rahmen ihrer täglichen Arbeit einsetzen, konnte das Gerät optimiert und an die Bedürfnisse aller Patienten angepasst werden. 

Der REAplan® 3.4 kann jetzt für die Behandlung von allen Patienter, unabhängig von der schwere und Art ihrer Erkrankung in jeder Phase der Rehabilitation eingesetzt werden. Zudem kann das Gerät über jede technische Plattform jedweder Konfiguration und Größe betrieben werden. 


Was sind seine neuen Funktionen ?

  • Vergrößerter Bereich der Höhenverstellung: Der Bereich der Höhenverstellung wurde um 25cm vergrößert, was die Anpassung an die Bedürfnisse des Patienter sowohl in sitzender als auch in stehender Position verbessert. Die minimale Höhe liegt nun bei 58cm und die maximale Höhe bei 124cm.
  • Bessre Zugänglichkeit für den Patienten : Dank der Neupositionierung des Schaltkastens (20cm tiefer und 45cm weiter hinten) gibt es mehr Platz für alle Arten von Rollstühlen. Patienten können nun auch mit ausgefahrenen Beinen an dem REAplan® 3.4 behandelt werden.
  • Verbesserte Robustheit : Das Gerät ist jetzt mit 4 statt 2 Beinen ausgestattet, was seine Stabilität verbessert.
  • Integration von Lenkrädern : Der Roboter ist mobil und kann so leicht in Ihrem Reha-Übungsraum bewegt werden. 

Der REAplan®, jetzt auch für spastische Patienten


Dank neuer Funktionen in der REAplan-Software konnten wie die Anwendung für Patienter mit schewerer Spastik verbessern. Diese Aktualisierung ermöglicht eine kontinuierliche Anpassung der Viskosität der Bewegung des Endeffektor-Griffs in Bezug auf die Spastizität des Patienten. Darüber hinaus haben wir eine Verbindung zwischen der Viskosität des Bewegungen und dem REAplan-Protokoll zur Bewertung der Spastizität hergestellt. Diese Verbindung ermöglicht es, die Dämpfung objektiv und quantitativ an die Bedürfniss und die Entwicklung des Patienter anzupassen. 

Wenn Sie am REAplan interessiert sind, klicken Sie auf die Schaltfläche unter und füllen Sie das Formular aus. 

New Chief Medical Officer (CMO) started at Axinesis from the 1st of September !

Since the 1st of September, a new member has joined Axinesis. Maxime Gilliaux, physiotherapist, doctor in motor sciences and Executive MBA in health, is now our Chief Medical Officer. He becomes our clinical and research referent for all of our collaborators.

Can you introduce yourself in a few words?

My name is Maxime Gilliaux, the new Chief Medical Officer (CMO) at Axinesis. As far as my background is concerned, I am a physiotherapist, a doctor in motor sciences and also hold an Executive MBA in health.

I have had different experiences in clinical, research and management fields.

More specifically, I had the chance to work with a team of researchers, clinicians and engineers linked to UCL, including Julien Sapin, CTO and founder of Axinesis. Together, we produced the first scientific evidences on the interest of the REAplan in the evaluation and rehabilitation of cerebral palsy patients, both adults and children. In terms of management, I created and directed a research department in a rehabilitation hospital while at the same time being part of its management committee as clinical project manager.

I think that the synergy of these skills will be a real asset in my responsibilities as CMO at Axinesis.

What are your responsibilities at Axinesis?

Within Axinesis, I will be the clinical and research referent for patients, health professionals, scientists, authorities, and other collaborators.

My responsibilities will be to bring a clinical and research vision to the company. At the clinical level, we will develop with the team innovative solutions that meet the needs of the patient and the therapist. In addition, we will train them to use our devices in an optimal way. On the research side, we will work with a number of researchers to validate the clinical protocols through scientific publications. 

What is your favorite game on the REAtouch?

I like the REAcooking game because of its graphic and functional aspects for the patient. Moreover, I like cooking a lot and I am very greedy!

Proven effectiveness of early Robotic Assisted Therapy for upper limb rehabilitation after stroke

Workspace of REAplan

Study provides further evidence for the effectiveness of robot-assisted therapy in stroke upper limb rehabilitation

Robot-assisted therapy (RAT) is of significant interest in early rehabilitation, when neuroplasticity is high but motor control is frequently insufficient for patients to independently practice functional movements. Many patients with stroke experience persistent upper limb (UL) impairments. This single-blind, randomized, controlled trial[i] explored the impact of partially substituting conventional therapy (CT) with RAT on the three International Classification of Functioning, Disability and Health (ICF) domains.

MethodsWorkspace of REAplan

Forty-five patients with acute stroke were randomized to receive dose-matched interventions over nine weeks. The first received conventional therapy (CT). In the second group, four CT sessions per week (25%) were substituted by RAT using our REAplan® end-effector robot to perform a game moving the paretic hand along a trajectory, with the robot assisting as needed.

Assessments were performed by the same blinded evaluator at inclusion (T0), after the intervention (TI), and at six months after stroke (T2). They were:

  • Upper limb motor impairments – FMA-UE (motor control) and box and block test (BBT –gross manual dexterity)
  • Activity limitations – Wolf Motor Function Test (S-WMFT), and Abilhand and Activlim questionnaires
  • Social participation – subscore of the Stroke Impact Scale (SISsb).


Main findings were:

  • The RAT group performed a mean (SD) of 520 (437) movements per session.
  • The RAT group showed significantly greater improvement in gross manual dexterity than CT group (P = 0.02). Between T0 and T2, BBT scores improved from a mean of 3.0 (8.3) to 12.7 (17.3) blocks in RAT, but only from 3.8 (7.5) to 5.1 (9.8) blocks in the CT group.
  • UL motor activity improved more in the RAT than CT group (P= 0.02). Between T0 and T2, the S-WFMT score improved from a mean of 16% (21.4) to 39% (36.6) in RAT, but from 19% (23.6) to just 25% (33.1) in the CT group.
  • FMA-UE results showed a positive trend in favor of the RAT group (P = 0.058)
  • Social participation scores also improved significantly more in the RAT group (P = 0.01). Between T0 and T2, SISsb improved from a mean of 36% (21.4) to 59% (24.1) in the RAT group, but only from 45% (26.6) to 47% (31.5) in the CT group.

Discussion and conclusion

This study supports evidence that using RAT to partially substitute CT in the early rehabilitation phase is at least as effective, or even better, at improving UL and ADL function than CT alone. This study was also the first to assess the ICF social participation domain. The authors suggest greater improvements can be explained by the effect of the robotic device itself, which allows clinicians to deliver therapy using key motor recovery factors including high intensity and repetitive, task-oriented movement training.

Moreover, RAT’s long-term effectiveness is unrelated to post-rehabilitation lifestyle, with similar patient numbers from both groups returning either home or to a nursing home. The authors suggest their results should be confirmed in future multicentre studies involving larger participant numbers.

[i] Dehem S, et al. Effectiveness of upper-limb robotic-assisted therapy in the early rehabilitation phase after stroke: A single-blind, randomised, controlled trial. Ann Phys Rehabil Med (2019).